US-based biotechnology company Aldeyra Therapeutics has announced a public offering of shares of its common stock to raise funds required primarily for the continued development of its lead compound, ADX-102, and other product candidates.

Part of the raised proceeds will also be used for conducting research and development (R&D), and towards working capital and other general corporate purposes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Oncology Venture Sweden has announced a rights offering to raise Skr52.89m ($5.92m) in gross proceeds.

The offering includes up to 1.2 million shares of the company’s common stock at a price of Skr45 ($5.04) a share.

The proceeds from the offering will be used for multiple purposes including the in-licensing and the development of an anti-cancer oral tyrosine kinase inhibitor, and for securing the rights for three products for development in women’s cancers from 2X Oncology.

"Oncology Venture Sweden has announced a rights offering to raise Skr52.89m ($5.92m) in gross proceeds."

Part of the proceeds will also be used to produce LiPlaCis for the clinical studies in accordance with the agreement signed with Cadila Pharma.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Based in Denmark, Oncology Venture Sweden is a company focused on the R&D of anti-cancer drugs.

UK-based precision cancer immunotherapies developer Treos Bio has completed a financing round participated by a group of private investors.

The company has raised $8m from the round, proceeds from which are intended to be used for conducting the early stage human clinical trial of PolyPEPI, an immunotherapy cancer vaccine being developed by the company for colorectal cancer.

Swiss company Novimmune and South Korean pharmaceutical company LegoChem Biosciences will jointly evaluate an antibody drug conjugate candidate (ADC), under a research agreement signed between the two.

ADCs, unlike chemotherapy, target only cancer cells, while healthy cells are spared.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact